Literature DB >> 23968642

Mechanisms of dopamine transporter regulation in normal and disease states.

Roxanne A Vaughan1, James D Foster.   

Abstract

The dopamine (DA) transporter (DAT) controls the spatial and temporal dynamics of DA neurotransmission by driving reuptake of extracellular transmitter into presynaptic neurons. Many diseases such as depression, bipolar disorder, Parkinson's disease (PD), and attention deficit hyperactivity disorder (ADHD) are associated with abnormal DA levels, implicating DAT as a factor in their etiology. Medications used to treat these disorders and many addictive drugs target DAT and enhance dopaminergic signaling by suppressing transmitter reuptake. We now understand that the transport and binding properties of DAT are regulated by complex and overlapping mechanisms that provide neurons with the ability to modulate DA clearance in response to physiological demands. These processes are controlled by endogenous signaling pathways and affected by exogenous transporter ligands, demonstrating their importance for normal neurotransmission, drug abuse, and disease treatments. Increasing evidence supports the disruption of these mechanisms in DA disorders, implicating dysregulation of transport in disease etiologies and suggesting these processes as potential points for therapeutic manipulation of DA availability.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Parkinson's disease; amphetamine; attention deficit hyperactivity disorder; bipolar disorder; cocaine; drug addiction

Mesh:

Substances:

Year:  2013        PMID: 23968642      PMCID: PMC3831354          DOI: 10.1016/j.tips.2013.07.005

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  97 in total

1.  Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis.

Authors:  F J Lee; F Liu; Z B Pristupa; H B Niznik
Journal:  FASEB J       Date:  2001-04       Impact factor: 5.191

Review 2.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

3.  Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors.

Authors:  Agustin Zapata; Bronwyn Kivell; Yang Han; Jonathan A Javitch; Elizabeth A Bolan; David Kuraguntla; Vanaja Jaligam; Murat Oz; Lankupalle D Jayanthi; Devadoss J Samuvel; Sammanda Ramamoorthy; Toni S Shippenberg
Journal:  J Biol Chem       Date:  2007-10-08       Impact factor: 5.157

4.  Amphetamine and methamphetamine reduce striatal dopamine transporter function without concurrent dopamine transporter relocalization.

Authors:  Christopher L German; Glen R Hanson; Annette E Fleckenstein
Journal:  J Neurochem       Date:  2012-08-23       Impact factor: 5.372

5.  Dopamine transporters are phosphorylated on N-terminal serines in rat striatum.

Authors:  James D Foster; Benchaporn Pananusorn; Roxanne A Vaughan
Journal:  J Biol Chem       Date:  2002-05-06       Impact factor: 5.157

6.  X-ray structures of LeuT in substrate-free outward-open and apo inward-open states.

Authors:  Harini Krishnamurthy; Eric Gouaux
Journal:  Nature       Date:  2012-01-09       Impact factor: 49.962

7.  Systematic screening for DNA sequence variation in the coding region of the human dopamine transporter gene (DAT1).

Authors:  F Grünhage; T G Schulze; D J Müller; M Lanczik; E Franzek; M Albus; M Borrmann-Hassenbach; M Knapp; S Cichon; W Maier; M Rietschel; P Propping; M M Nöthen
Journal:  Mol Psychiatry       Date:  2000-05       Impact factor: 15.992

Review 8.  Regulation of dopamine transporter function by protein-protein interactions: new discoveries and methodological challenges.

Authors:  Jacob Eriksen; Trine Nygaard Jørgensen; Ulrik Gether
Journal:  J Neurochem       Date:  2010-01-18       Impact factor: 5.372

9.  The N terminus of monoamine transporters is a lever required for the action of amphetamines.

Authors:  Sonja Sucic; Stefan Dallinger; Barbara Zdrazil; René Weissensteiner; Trine N Jørgensen; Marion Holy; Oliver Kudlacek; Stefan Seidel; Joo Hwan Cha; Ulrik Gether; Amy H Newman; Gerhard F Ecker; Michael Freissmuth; Harald H Sitte
Journal:  J Biol Chem       Date:  2010-01-29       Impact factor: 5.157

10.  Dopamine transporter endocytic determinants: carboxy terminal residues critical for basal and PKC-stimulated internalization.

Authors:  Ekaterina Boudanova; Deanna M Navaroli; Zachary Stevens; Haley E Melikian
Journal:  Mol Cell Neurosci       Date:  2008-06-25       Impact factor: 4.314

View more
  130 in total

Review 1.  Investigating the underlying mechanisms of aberrant behaviors in bipolar disorder from patients to models: Rodent and human studies.

Authors:  Jordy van Enkhuizen; Mark A Geyer; Arpi Minassian; William Perry; Brook L Henry; Jared W Young
Journal:  Neurosci Biobehav Rev       Date:  2015-08-19       Impact factor: 8.989

2.  Environmental enrichment enhances synaptic plasticity by internalization of striatal dopamine transporters.

Authors:  Myung-Sun Kim; Ji Hea Yu; Chul Hoon Kim; Jae Yong Choi; Jung Hwa Seo; Min-Young Lee; Chi Hoon Yi; Tae Hyun Choi; Young Hoon Ryu; Jong Eun Lee; Bae Hwan Lee; Hyongbum Kim; Sung-Rae Cho
Journal:  J Cereb Blood Flow Metab       Date:  2015-11-02       Impact factor: 6.200

3.  Prior nicotine self-administration attenuates subsequent dopaminergic deficits of methamphetamine in rats: role of nicotinic acetylcholine receptors.

Authors:  Michelle G Baladi; Shannon M Nielsen; J Michael McIntosh; Glen R Hanson; Annette E Fleckenstein
Journal:  Behav Pharmacol       Date:  2016-08       Impact factor: 2.293

4.  Palmitoylation by Multiple DHHC Enzymes Enhances Dopamine Transporter Function and Stability.

Authors:  Danielle E Bolland; Amy E Moritz; Daniel J Stanislowski; Roxanne A Vaughan; James D Foster
Journal:  ACS Chem Neurosci       Date:  2019-04-19       Impact factor: 4.418

Review 5.  The Deleterious Effects of Oxidative and Nitrosative Stress on Palmitoylation, Membrane Lipid Rafts and Lipid-Based Cellular Signalling: New Drug Targets in Neuroimmune Disorders.

Authors:  Gerwyn Morris; Ken Walder; Basant K Puri; Michael Berk; Michael Maes
Journal:  Mol Neurobiol       Date:  2015-08-27       Impact factor: 5.590

Review 6.  Functional mechanisms of neurotransmitter transporters regulated by lipid-protein interactions of their terminal loops.

Authors:  George Khelashvili; Harel Weinstein
Journal:  Biochim Biophys Acta       Date:  2015-04-04

Review 7.  The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson's Disease.

Authors:  Phillip Mackie; Joe Lebowitz; Leila Saadatpour; Emily Nickoloff; Peter Gaskill; Habibeh Khoshbouei
Journal:  Brain Behav Immun       Date:  2018-03-15       Impact factor: 7.217

8.  AAH2 gene is not required for dopamine-dependent neurochemical and behavioral abnormalities produced by Toxoplasma infection in mouse.

Authors:  Ross McFarland; Zi Teng Wang; Yan Jouroukhin; Ye Li; Olga Mychko; Isabelle Coppens; Jianchun Xiao; Lorraine Jones-Brando; Robert H Yolken; L David Sibley; Mikhail V Pletnikov
Journal:  Behav Brain Res       Date:  2018-03-16       Impact factor: 3.332

9.  miR-137 and miR-491 Negatively Regulate Dopamine Transporter Expression and Function in Neural Cells.

Authors:  Xiaojian Jia; Feng Wang; Ying Han; Xuewen Geng; Minghua Li; Yu Shi; Lin Lu; Yun Chen
Journal:  Neurosci Bull       Date:  2016-09-15       Impact factor: 5.203

10.  Fast-scan cyclic voltammetry demonstrates that L-DOPA produces dose-dependent, regionally selective bimodal effects on striatal dopamine kinetics in vivo.

Authors:  Rashed Harun; Kristin M Hare; Elizabeth M Brough; Miranda J Munoz; Christine M Grassi; Gonzalo E Torres; Anthony A Grace; Amy K Wagner
Journal:  J Neurochem       Date:  2016-01-13       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.